Huaren Pharmaceutical Co., Ltd. (SHE:300110)
China · Delayed Price · Currency is CNY 3.150
0.00 (0.00%)
Apr 30, 2026, 3:04 PM CST
Huaren Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -459.46 | -459.39 | -1,368 | 188.06 | 180.78 | 130.4 |
Depreciation & Amortization | 108.47 | 108.47 | 116.68 | 126.85 | 149.59 | 134.94 |
Other Amortization | 8.22 | 8.22 | 10.25 | 8.55 | 11.02 | 16.45 |
Loss (Gain) From Sale of Assets | -0.01 | -0.01 | -0.02 | -4.35 | -13.86 | -0.11 |
Asset Writedown & Restructuring Costs | 563.5 | 563.5 | 87.57 | 7.03 | 6.69 | 0.28 |
Loss (Gain) From Sale of Investments | -2.34 | -2.34 | -0.36 | -0.84 | 1.39 | 0.87 |
Provision & Write-off of Bad Debts | - | - | 9.86 | -48.21 | 38.66 | 42.19 |
Other Operating Activities | -17.46 | 64.87 | 1,412 | 130.73 | 75.7 | 111.27 |
Change in Accounts Receivable | 51.63 | 51.63 | 172.59 | 9.02 | 135.83 | -1,307 |
Change in Inventory | 56.26 | 56.26 | 9.11 | -58.03 | 8.62 | -2.18 |
Change in Accounts Payable | 15.81 | 15.81 | -108.13 | -63.84 | -361.01 | 303.49 |
Operating Cash Flow | 307.83 | 390.23 | 322.36 | 305.6 | 217.98 | -578.52 |
Operating Cash Flow Growth | -0.22% | 21.05% | 5.49% | 40.19% | - | - |
Capital Expenditures | -28.03 | -48.98 | -24.69 | -45.86 | -42.33 | -27.86 |
Sale of Property, Plant & Equipment | 0.02 | 0.02 | 0.03 | 10.03 | 26.43 | 0.07 |
Cash Acquisitions | - | - | -13.67 | -61.61 | -128 | -431.8 |
Divestitures | 1.71 | 1.71 | - | - | - | - |
Investment in Securities | 0 | 0 | 0.06 | - | - | - |
Other Investing Activities | 0.36 | 0.36 | 0.36 | 0.3 | 0.09 | 1.01 |
Investing Cash Flow | -25.94 | -46.89 | -37.92 | -97.14 | -143.81 | -458.58 |
Long-Term Debt Issued | - | 538.85 | 843.33 | 1,498 | 2,010 | 1,995 |
Long-Term Debt Repaid | - | -885.25 | -1,129 | -1,606 | -2,179 | -694 |
Net Debt Issued (Repaid) | -253.36 | -346.4 | -285.79 | -108.26 | -169.12 | 1,301 |
Common Dividends Paid | -39 | -42.46 | -78.9 | -86.15 | -89.38 | -71.38 |
Other Financing Activities | -5.93 | -5.93 | -4.82 | 73.69 | 105.84 | -189.23 |
Financing Cash Flow | -298.29 | -394.8 | -369.5 | -120.72 | -152.67 | 1,040 |
Foreign Exchange Rate Adjustments | -0 | 0 | 0 | -0 | -0 | -0.02 |
Net Cash Flow | -16.41 | -51.45 | -85.07 | 87.74 | -78.5 | 3.03 |
Free Cash Flow | 279.79 | 341.25 | 297.67 | 259.74 | 175.65 | -606.38 |
Free Cash Flow Growth | 3.61% | 14.64% | 14.60% | 47.87% | - | - |
Free Cash Flow Margin | 21.07% | 25.82% | 22.00% | 15.87% | 10.85% | -38.85% |
Free Cash Flow Per Share | 0.24 | 0.29 | 0.25 | 0.22 | 0.15 | -0.51 |
Cash Income Tax Paid | 114.29 | 119.12 | 138.89 | 183.31 | 146.47 | 183.03 |
Levered Free Cash Flow | 369.53 | 115.96 | 1,632 | 293.17 | 143.72 | -634.17 |
Unlevered Free Cash Flow | 369.53 | 115.96 | 1,666 | 331.61 | 183.82 | -594.71 |
Change in Working Capital | 106.9 | 106.9 | 55.04 | -102.22 | -231.97 | -1,015 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.